LUMATEPERONE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).

How it works

Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6; undergoes glucuronidation and oxidation; active metabolite is lumateperone N-desmethyl.
Excretion	Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Half-life	Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Protein binding	Approximately 97.4% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is about 4.7 L/kg (based on 60 kg), indicating extensive tissue distribution.
Bioavailability	Oral bioavailability is approximately 2–4% due to extensive first-pass metabolism. Food increases AUC by approximately 1.6-fold.
Onset of Action	Oral: Clinical effects are observed within 1–2 weeks of daily dosing, with some improvement noted as early as week 1 in clinical trials.
Duration of Action	Maintained over 24 hours with once-daily oral administration. The long half-life supports sustained therapeutic coverage.

Classification & Brands

Dosing & administration

42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.

Dosage form	CAPSULE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR 15-29 mL/min), dose reduction to 21 mg orally once daily. Not recommended in end-stage renal disease (eGFR <15 mL/min).
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 21 mg orally once daily. Child-Pugh Class C: not recommended.
Pediatric use	Safety and efficacy not established in pediatric patients; no approved dosing guidelines available.
Geriatric use	Use with caution due to increased sensitivity to hypotension and sedation. Initiate at 21 mg orally once daily for 7 days, then increase to 42 mg once daily if tolerated. Monitor for orthostatic hypotension and falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).

Breastfeeding	Excretion into breast milk is unknown; no available M/P ratio. Due to potential for adverse reactions (e.g., sedation, extrapyramidal effects) in breastfed infants, breastfeeding is not recommended during treatment.
Teratogenic Risk	Teratogenic risk is not established; animal studies show no evidence of harm at doses up to 10 times the maximum recommended human dose. However, human data are insufficient to rule out risk. First trimester: limited data, risk cannot be excluded. Second and third trimesters: antipsychotics may cause extrapyramidal symptoms or withdrawal in neonates. Risk-benefit assessment recommended.

Warnings & precautions

■ FDA Black Box Warning

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lumateperone is not approved for the treatment of patients with dementia-related psychosis.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to lumateperone or any components of the formulation"]

Clinical Precautions

Precautions

["Cerebrovascular adverse reactions in elderly with dementia","Neuroleptic malignant syndrome","Tardive dyskinesia","Metabolic changes (hyperglycemia, dyslipidemia, weight gain)","Leukopenia and neutropenia","Orthostatic hypotension and syncope","Seizures","Potential for cognitive and motor impairment","QT prolongation"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LUMATEPERONE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).

How it works

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6; undergoes glucuronidation and oxidation; active metabolite is lumateperone N-desmethyl.
Excretion	Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Half-life	Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Protein binding	Approximately 97.4% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is about 4.7 L/kg (based on 60 kg), indicating extensive tissue distribution.
Bioavailability	Oral bioavailability is approximately 2–4% due to extensive first-pass metabolism. Food increases AUC by approximately 1.6-fold.
Onset of Action	Oral: Clinical effects are observed within 1–2 weeks of daily dosing, with some improvement noted as early as week 1 in clinical trials.
Duration of Action	Maintained over 24 hours with once-daily oral administration. The long half-life supports sustained therapeutic coverage.

Classification & Brands

Dosing & administration

42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.

Dosage form	CAPSULE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR 15-29 mL/min), dose reduction to 21 mg orally once daily. Not recommended in end-stage renal disease (eGFR <15 mL/min).
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 21 mg orally once daily. Child-Pugh Class C: not recommended.
Pediatric use	Safety and efficacy not established in pediatric patients; no approved dosing guidelines available.
Geriatric use	Use with caution due to increased sensitivity to hypotension and sedation. Initiate at 21 mg orally once daily for 7 days, then increase to 42 mg once daily if tolerated. Monitor for orthostatic hypotension and falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).

Breastfeeding	Excretion into breast milk is unknown; no available M/P ratio. Due to potential for adverse reactions (e.g., sedation, extrapyramidal effects) in breastfed infants, breastfeeding is not recommended during treatment.
Teratogenic Risk	Teratogenic risk is not established; animal studies show no evidence of harm at doses up to 10 times the maximum recommended human dose. However, human data are insufficient to rule out risk. First trimester: limited data, risk cannot be excluded. Second and third trimesters: antipsychotics may cause extrapyramidal symptoms or withdrawal in neonates. Risk-benefit assessment recommended.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to lumateperone or any components of the formulation"]

Clinical Precautions

Precautions

Clinical Tips & Counseling

Drug interactions

Loading safety data…